Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics.
about
African Americans with asthma: genetic insightsPharmacogenetics, pharmacogenomics and airway diseaseThe reality of pharmacogenomics: optimizing therapeutic decision makingLimited beta2-adrenoceptor haplotypes display different agonist mediated airway responses in asthmaticsA genome-wide association study of bronchodilator response in asthmaticsA multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.What is new with the beta2-agonists: issues in the management of asthma.The role of pharmacogenomics in improving the management of asthmaPharmacogenomic approaches to asthma treatment.Pharmacogenomics to predict drug response.Pharmacogenomics of pediatric asthma.Recent developments in the genetics of asthma.Pharmacogenetics of asthma.Beta-adrenergic receptor polymorphisms and drug responses in asthma.Antagonism of long-acting beta2-adrenoceptor agonism.Pharmacogenomics: the future of drug therapy.Very important pharmacogene summary ADRB2.Prediction of individual response to anticancer therapy: historical and future perspectivesPharmacogenetics in drug development.Asthma pharmacogenetics and the development of genetic profiles for personalized medicinePharmacogenomics: marshalling the human genome to individualise drug therapyManagement of asthma in adults: current therapy and future directionsEvaluation of spirometry values in relation to beta-2-adrenergic receptor gene polymorphism.Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma.Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism.Polymorphisms in the beta2 adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness, and rate of decline in lung function in smokers.Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterolModest genetic influence on bronchodilator response: a study in healthy twins.Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology.Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotypeThe arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterolDrug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).Pharmacogenetics-based new therapeutic concepts.How pharmacogenomics will play a role in the management of asthma.Pharmacogenomics of beta2-agonist: key focus on signaling pathways.Acceptance of Asthma Pharmacogenetic Study by Children and AdultsDevelopment of a Pharmacogenetic Predictive Test in asthma: proof of concept.Recent development in pharmacogenomics: from candidate genes to genome-wide association studies.Non-corticosteroid therapy for the long-term control of asthma.Pharmacogenetics of the response to beta 2 agonist drugs: a systematic overview of the field.
P2860
Q24648561-D2F9C6C9-8B7C-4880-B6F7-BC944502FFA9Q24798917-2BC0783B-BA5A-4213-A1D5-36F0C6008C68Q24815907-2C262F92-EB58-4A7D-B8E5-C759A3929524Q25257368-E902CAA3-2BAA-47DB-8BBD-724124F278D9Q28943426-35F927B4-5DC0-4702-86AB-3005AC5D3CD9Q31080865-3E93FC30-669B-4710-ADC8-4ABAE199BB18Q33213762-515E92AD-E2EE-44E1-B60E-5699F585043BQ33669054-2D50B209-D69A-41A6-BCD8-946DE976A753Q33940766-681799F2-7FB2-4E94-BEC6-47D3D1B22DE9Q34189894-DB49D315-A232-41FF-96FD-C46AD6341360Q34436523-E84A5393-1FC5-47AA-A1DD-44B2FE31CA38Q34448286-05BE7947-5A6A-4C21-8C08-F76DF34A6D85Q34534425-7753A020-9022-4468-9F28-259BF996B237Q34612106-0BBD37CA-45C7-41CA-8FE2-D160407C206CQ34866359-8BF18A5D-9B5F-4CB0-88A2-DA89140B6885Q34952587-B8CD995F-8F0B-4115-B0E5-4E672507E6B5Q34994884-3CC93798-7632-447E-9518-C1DC8C4C3BB6Q35024682-B278C4FE-E2CE-4AF4-9D5B-5E1F6942AF66Q35038056-FC1839F9-41B0-4BD8-91D3-FEEBAC51D612Q35076452-0C174011-C7DE-499E-A0D7-5520BDD0FDA9Q35090217-A7F7AEFF-7703-46B7-8D3B-69802A0AB7F2Q35143482-743960DD-C81B-4F06-81BD-489636702320Q35179106-E8D7A13E-1E02-4F51-A240-B8E021B79FEBQ35525863-F483C84D-58E5-4A2A-A4E0-79F29E4C1E2DQ35534065-FAEDC225-BA0A-4387-BBAD-285034D190FBQ35536131-9141EE78-AB52-4275-8409-4F30B31260C2Q35536841-34A22C24-7B34-45B1-913E-329D58DCC400Q35539568-88090EDB-6C9C-4F95-B3CE-296BB58E4992Q35693323-641234A4-79D1-4C63-9EF9-FD581F052885Q35825639-F02C06B3-AA59-418A-93E7-A1AD3D176F6BQ35825894-20FB935A-2251-48BA-A58A-540A78502EFDQ35826495-B0C83A3C-98D3-4CA9-AAF3-87EBA89883EFQ35956177-40C811C2-BD9D-492F-976E-FF8BB39B09A2Q36075209-D1D8E71F-1DF0-43D6-9009-6A768CBED818Q36596722-248D5C50-C803-41C6-9CF2-B2D61C4E837BQ36734679-2560C9A4-742E-41F9-925F-F5E940F14A2CQ36845596-D051D0CC-7AF1-4A02-901C-1F334C15F59CQ36874335-D5310886-A72C-4C07-875C-B6967EBEDB2DQ36916911-861FF421-A787-438A-B1D2-8828D7CE3B2DQ36918110-191D29C3-BE95-46BE-B3FF-DB4B70121EC0
P2860
Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Impact of genetic polymorphism ...... onchodilator pharmacodynamics.
@en
type
label
Impact of genetic polymorphism ...... onchodilator pharmacodynamics.
@en
prefLabel
Impact of genetic polymorphism ...... onchodilator pharmacodynamics.
@en
P2093
P1476
Impact of genetic polymorphism ...... ronchodilator pharmacodynamics
@en
P2093
P304
P356
10.1016/S0009-9236(99)70071-8
P407
P577
1999-05-01T00:00:00Z